• Gilead sets list price of remdesivir in Covid-19 for U.S. commercial payers, developed countries

    9 days ago - By MedCity News

    The company determined a price of $520 per vial for U.S. payers and $390 for government payers outside the U.S., the latter price being designed to avoid the need for country-by-country pricing negotiations, CEO Daniel O'Day wrote in an open letter.
    Read more ...

     

  • STAT Plus: Pharmalittle: Pharma giants plan $1 billion antibiotic venture; Gilead prices remdesivir below most estimates

    STAT Plus: Pharmalittle: Pharma giants plan $1 billion antibiotic venture; Gilead prices remdesivir below most estimates

    9 days ago - By STAT

    Good morning, everyone, and welcome to another working week. We hope the weekend respite was somehow relaxing and refreshing. After all, a break is a break. Now, though, the predictable round of Zoom and Skype meetings has returned. So time to get ready and we are doing so by brewing a few cups of delicious stimulation - maple bourbon, in this instance. Feel free to join us. Remember, no prescription is required. Meanwhile, here are a few tidbits to get you going on your own journey. Hope you have a useful day and do keep in touch...
    Amid escalating concerns over antibiotic resistance...
    Read more ...

     

  • Gilead announces long-awaited price for Covid-19 drug remdesivir

    9 days ago - By STAT

    Since remdesivir became the first medicine shown to have an impact on Covid-19, doctors, politicians, and Wall Street investors have engaged in a tense guessing game : What would its maker, Gilead Sciences, charge for the drug?
    Now there is an answer.
    Read more ...